Axsome Therapeutics, Inc. (AXSM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$206.68-0.80%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue reaches at least $638.5 million in 2026: FY26 revenue guidance $0.0M vs $638.5M target.
Axsome aims to grow revenue to about $638 million in 2026. It improved operating income from -$78M to -$63M recently. The company settled SUNOSI patent lawsuits, reducing legal risks.
Axsome still loses money and faces legal risks from patent issues. Revenue growth may slow below expectations. Operating income improvement is limited and may stall.
The price is about 12% above our fair value near $220. Analysts expect 73% revenue growth, which the market mostly prices in.
Breaks if: Operating income remains worse than -$63.36 million in 2026-Q1
Focus on reducing operating losses through cost management and scaling commercial operations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. AXSM is currently loss-making and has shown weak recent financial performance, but it operates in a sector that has favorable momentum.
The market appears to have priced in a low expectations gap, indicating that investors are not overly optimistic about AXSM's near-term performance. Valuation is aligned with peers, but AXSM trades at a premium, suggesting some caution is warranted.
Management is focused on increasing revenue growth and advancing its drug pipeline, which has seen some success. However, recent financial performance has been weak, and there is a moderate risk of missing future earnings expectations.
The long-term thesis hinges on management's ability to maintain revenue growth and successfully advance its drug pipeline. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping AXSM's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $638.5 million in 2026
Drive robust commercial growth of AUVELITY, SUNOSI, and SYMBRAVO products with expanded sales force and new indications.
Stated as a priority in 2 of last 2 quarters. Total net product revenue grew from $191.2 million in 2026-Q1 to $218.4 million in 2026-Q2, representing 46-57% year-over-year growth. AUVELITY sales increased 51% year-over-year in 2Q 2026, and SYMBRAVO sales grew 461% year-over-year. The trajectory is delivering robust commercial growth consistent with management's stated focus.
“Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth.”
“Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth.”
Breaks if: New patent litigation or unresolved legal issues arise on SUNOSI
In the next 1 to 3 years, AXSM's performance will depend on execution and market conditions. Not investment advice.